Theratechnologies’ HIV Candidate Meets Primary Endpoint in Phase 3

Theratechnologies’ Phase 3 trial for HIV candidate ibalizumab met its primary endpoint a Phase 3 trial.

Preliminary results show that 82.5 percent of patients enrolled in the study saw a decreased viral load following seven days of treatment, a result that is statistically significant and “better than results observed during the control period.”